This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Stone, MD Mount Sinai Health System tim.hodson Wed, 04/02/2025 - 15:26 March 31, 2025 Using intravascular imaging (IVI) to guide stent implantation during complex stenting procedures is safer and more effective for patients with severely calcified coronary artery disease than conventional angiography, the more commonly used technique.
Background Drug-eluting stents (DESs) have become the gold standard of coronary angioplasty since their inception in 2002. We aimed to compare outcomes between a broad range of second-generation DP-DES and BP-DES in an all-comer population. vs 57.5%, p=0.010), a greater average number of stents implanted per patient (1.72±0.92
and an investigator in the VIVID study , which contributed to the device’s FDA approval – successfully used the Duo Venous Stent System for the first time outside of a clinical trial. Duo Hybrid has a distinct integrated design that combines multiple zones of differing mechanical properties into a single stent [3].
BackgroundThe left subclavian artery (LSA) can be intentionally covered by a stent graft to acquire adequate landing zones for a proximal entry tear near the LSA during thoracic endovascular aortic repair (TEVAR). The Castor single-branched stent graft is designed to treat type B aortic dissection (TBAD) to retain the LSA during TEVAR.
Smits and a distinguished team of international researchers, the trial compares the performance of SMT's biodegradable-polymer sirolimus-eluting Supraflex Cruz stent with the biodegradable-polymer Ultimaster Tansei * stent in patients with high bleeding risk (HBR) undergoing abbreviated dual antiplatelet therapy (DAPT).
BACKGROUND:In patients with post-thrombotic syndrome, stent recanalization of iliofemoral veins or the inferior vena cava can restore venous patency and improve functional outcomes. The risk of stentthrombosis is particularly increased during the first 6 months after intervention. points (P=0.36), respectively.
Venita Chandra, director of vascular surgery, Stanford University School of Medicine, showed that DA followed by DCB achieved a significantly lower provisional stent rate with comparable safety and efficacy outcomes compared to standard predilatation prior to DCB, making it a viable alternative for treating long and highly calcified lesions.
Background For high bleeding-risk patients (HBR) undergoing percutaneous coronary intervention (PCI), the LEADERS FREE (LF) and LEADERS FREE II (LF II) trials established the safety and efficacy of a stainless steel polymer-free biolimus-coated stent (SS-BCS) with 30 days of dual antiplatelet treatment (DAPT). to 9.2%) patients.
In order to improve treatment outcomes in these difficult cases, the use of stent‐assisted embolization has been attempted in endovascular treatment of intracranial aneurysms. Thromboembolic complications were observed in one patient, with the clinical outcome of death due to basilar stentthrombosis.
Background Bioresorbable vascular scaffolds (BVS) were designed to reduce the rate of late adverse events observed in conventional drug-eluting stents (DES) by dissolving once they have restored lasting patency. All other outcomes were statistically equivalent. to 1.70; p=0.01) resulting from high rates of TVMI and ID-TLR.
The outcome was any 30-day event defined as death, stentthrombosis, major bleeding events, and composites of ischemic and bleeding events. There was no statistically significant difference in death or composite outcomes between groups (Table 2).
The 2 coprimary outcomes were target lesion revascularization and myocardial infarction. The secondary outcomes included ischemia-driven target lesion revascularization, target vessel myocardial infarction, death, cardiac death, target vessel revascularization, stentthrombosis, and major adverse cardiac events.
All patients had headache, and funduscopic examination demonstrated papilledema for all patients. All patients had headache, and funduscopic examination demonstrated papilledema for all patients. All patients had headache, and funduscopic examination demonstrated papilledema for all patients.
There are conflicting sources regarding the relationship between hyperglycemia and outcomes in STEMI patients. We aimed to compile evidence to assess the association between hyperglycemia and adverse outcomes. Mortality was the most often outcome reported related to hyperglycemia. 3.45) and 4.47 (95% CI: 2.54–7.87),
BackgroundBehcet's disease (BD) is a systematic vasculitis that affects vessels with various sizes, presenting as venous thrombosis and arterial pseudoaneurysms.
Colchicine, a cheap and widely used anti-inflammatory has shown promise in improving cardiovascular outcomes. Results The use of colchicine in patients who underwent PCI significantly reduced MACE outcomes (risk ratio 0.73 (95% CI 0.61 This has been shown to increase the likelihood of further major adverse cardiovascular events (MACE).
There was no difference in net adverse clinical outcomes and each component of coprimary cardiovascular end point. 3.30]) and subacute definite or probable stentthrombosis (0.58% and 0.17%; hazard ratio, 3.40 [95% CI, 1.26–9.23]) years; men, 76.6%; acute coronary syndrome, 75.0%). 1.45];Pnoninferiority=0.01).
Background:Stopping aspirin within 1 month after implantation of a drug-eluting stent (DES) for ticagrelor monotherapy has not been exclusively evaluated for patients with acute coronary syndrome (ACS). Circulation, Ahead of Print. versus 3.4%; HR, 0.35 [95% CI, 0.20–0.61];P<0.001).Conclusions:This 0.61];P<0.001).Conclusions:This
However, whether the addition of OCT to angiography to guide percutaneous coronary intervention (PCI) of complex lesions affects clinical outcomes is debated.Methods:A systematic search for randomized controlled trials (RCTs) was conducted using PubMed, Scopus, and Cochrane databases through September 2024.
Patient characteristics and clinical outcomes were collected via electronic medical record system. The primary outcome was major adverse cardiac and cerebrovascular event (MACCE), namely a composite of death from cardiovascular causes, myocardial infarction (MI), stroke, stentthrombosis within 12 month.
Upon removal of its retrieval hook, the filter's legs are intended to expand, forming a stent-like structure that is suitable for long-term residence in the human body. For younger or thrombophilic patients, careful evaluation of the filter's suitability and extended follow-up are crucial to optimize outcomes.
This study aimed to evaluate the clinical outcomes of intravascular imaging–guided PCI compared with angiography‐guided PCI.Methods and ResultsA random‐effects meta‐analysis was performed on the basis of the intention‐to‐treat principle. The primary outcomes were major adverse cardiac events, cardiac death, and all‐cause death.
Old ‘NSTEMI’ A history of coronary artery disease and a stent to the same territory further increases pre-test likelihood of acute coronary occlusion, including in-stentthrombosis. The patient had a history of ‘NSTEMI’ a decade prior, with an RCA stent. Does this change your interpretation?
BackgroundProcedural intravenous cangrelor has been proposed as an effective platelet inhibition strategy for stenting in acute ischemic stroke. Safety outcomes included rates of symptomatic intracranial hemorrhage, parenchymal hematoma type 2, petechial hemorrhage, and in‐stentthrombosis. 3.28];P=0.836).
Methods A search was conducted on five databases for randomised controlled trials (RCTs) conducted between 1 January 2000 and 17 July 2022, which included an ADP-specific platelet function assays and P2Y 12 antagonists as part of dual antiplatelet therapy (DAPT) and have reported the efficacy and/or safety outcomes.
Efficacy outcomes included the major adverse cardiovascular events outcome and safety outcomes included minor and major bleedings. We performed a frequentist network meta-analysis. Results Nine studies (n=35 441 patients) were included in the systematic review.
If the FFR normalizes after stenting, the restenosis rates at six months is less than 5%. Since the FFR wire can be used for guiding balloon catheters and stents, it is easy to make post procedure measurements without any additional effort. Routine FFR measurement probably lead to more judicious use of stents and improved outcomes.
Other outcomes were comparable in both groups. Major ischemic outcomes were similar. Data were extracted from published reports and quality assessment was performed per Cochrane recommendations. Major bleeding [hazard ratio 0.47; 95% confidence interval (CI), 0.37–0.61; 0.61; P < 0.001], NACE (hazard ratio 0.71; 95% CI, 0.56–0.90;
Cardiovascular medications frequently lead this category, often contributing to adverse clinical outcomes, including emergency department visits and hospitalizations. In recent years, numerous health care challenges have been tackled, some making headlines, while others quietly escalate under the radar – like polypharmacy.
In the early years of percutaneous coronary intervention (PCI), studies indicated a heightened risk of major adverse cardiac events (MACE) in patients with reduced left ventricular ejection fraction (LVEF), involving outcomes such as death, Q-wave myocardial infarction (MI), stentthrombosis, and repeat revascularization.
We therefore aim to characterize the antiplatelet regimens, and associated thromboembolic/hemorrhagic outcomes, utilized in patients with aneurysms treated with PED Shield.MethodsFactors including demographics, comorbidities, rupture status, devices placed, and antiplatelet regimen, among others, were collected.
A meta-analysis was performed on primary outcomes of major adverse cardiac events (MACE) and all-cause mortality. A random-effects model was used for outcomes with high heterogeneity.Results:We included 4 RCTs with 3173 patients comparing FFR-guided CR with culprit-only PCI in patients with STEMI and multivessel coronary artery diseases.
It is important to recognize that coronary thrombosis is dynamic , with spontaneous opening and lysing of the thrombus in the infarct-related artery (we all have endogenous tPA and plasmin to lyse thrombi). It was stented. Silent ischemia as a marker for early unfavorable outcomes in patients with unstable angina.
A man in his 70s with past medical history of hypertension, dyslipidemia, CAD s/p left circumflex stent 2 years prior presented to the ED with worsening intermittent exertional chest pain relieved by rest. Yet this is rarely followed, and patient outcomes like this are the result once in a while. Am J Emerg Med. 2014;32:e5–e8.
She was noted to have incidental left internal jugular (IJ) vein thrombosis for which anticoagulation was held in the setting of recent neurosurgical procedure and SAH. After the second treatment, she had improvement in speech and motor strength. Systolic blood pressure goal was gradually normalized. She was discharged home on HD20.ConclusionWe
The percent change from baseline in fasting triglycerides (TG) at six months served as the primary outcome measure. The percent change from baseline in fasting TG at six months served as the primary outcome measure. Among patients with HFpEF, those who received the shunt experienced poor outcomes than those who did not.
We included major adverse cardiovascular events (MACE), myocardial infarction (MI), cardiac death and other outcome indicators. ConclusionsCompared with the non-IVUS-guided group, IVUS-guided stent implantation may be more effective for patients with complex CAD.Systematic Review RegistrationPROSPERO [CRD42024531366].
BackgroundWhile several studies have explored the outcomes of transcatheter interventions for modified Blalock–Taussig shunts (MBTSs) in a broad range of congenital heart diseases, none have specifically examined the interventions in patients with hypoplastic left heart syndrome (HLHS) who underwent Norwood palliation (NP).MethodsThis
We describe the single center experience of a series of patients treated with endovascular stent grafting for large aneurysms after previous surgery for CoA.MethodsThis series involves 12 consecutive patients treated with endovascular stent grafting from April 2003 to January 2022 for late aneurysm at the site of previous surgical repair for CoA.
After stent deployment, we often see improvement in the ST-T within seconds or minutes. Here is the final angiogram following placement of a stent in the ostial RCA. 2:04 PM, post stent deployment You can see that even after complete restoration of flow, the ECG still looks terrible, V most of all.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content